News
BMY
57.87
-0.18%
-0.11
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now
The Motley Fool · 1d ago
2 Healthcare Stocks to Buy for Their Dividends -- and Why Pfizer Isn't One of Them
Barron‘s · 1d ago
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
The Motley Fool · 1d ago
SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn
Seeking Alpha · 1d ago
My Top 5 Pharma Stocks Wall Street Ignores
Seeking Alpha · 2d ago
Bristol-Myers Squibb Price Target Maintained With a $54.00/Share by Cantor Fitzgerald
Dow Jones · 2d ago
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $54 Price Target
Benzinga · 2d ago
Weekly Report: what happened at BMY last week (0629-0703)?
Weekly Report · 2d ago
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.
The Motley Fool · 2d ago
Bristol Myers Squibb: Pain First, Payoff Later?
Seeking Alpha · 4d ago
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
NASDAQ · 5d ago
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes
Seeking Alpha · 5d ago
BMY’s Shift Into Russell Value Defensive Indexes Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
Simply Wall St · 6d ago
Roche lung cancer therapy beats rivals from Amgen, BMS in late-stage trial
Seeking Alpha · 6d ago
Bristol Myers Squibb (BMY) Joins Defensive Value Indexes, Is It Still 8% Undervalued?
Simply Wall St · 07/01 20:45
Four stock-moving events to watch as FDA revives AdComs
Seeking Alpha · 07/01 17:51
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
NASDAQ · 07/01 13:11
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 07/01 11:50
Dell Technologies Now #100 Largest Company, Surpassing Bristol Myers Squibb
NASDAQ · 06/30 20:42
Bristol Myers Squibb Moves Up In Market Cap Rank, Passing Starbucks
NASDAQ · 06/30 20:42
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).